Modified Weekly Cisplatin-based Chemotherapy is Acceptable in Postoperative Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2015 Mar 21

PMID 25793192

Citations 8

Authors

Hsueh-Ju Lu

Chao-Chun Yang

Ling-Wei Wang

Pen-Yuan Chu

Shyh-Kuan Tai

Ming-Huang Chen

Muh-Hwa Yang

Peter Mu-Hsin Chang

Affiliations

Soon will be listed here.

Abstract

Background: Triweekly cisplatin-based postoperative concurrent chemoradiotherapy (CCRT) has high intolerance and toxicities in locally advanced head and neck cancer (LAHNC). We evaluated the effect of a modified weekly cisplatin-based chemotherapy in postoperative CCRT.

Methods: A total of 117 patients with LAHNC were enrolled between December 2007 and December 2012. Survival, compliance/adverse events, and independent prognostic factors were analyzed.

Results: Median follow-up time was 30.0 (3.1-73.0) months. Most patients completed the entire course of postoperative CCRT (radiotherapy ≥ 60 Gy, 94.9%; ≥ 6 times weekly chemotherapy, 75.2%). Only 17.1% patients required hospital admission. The most common adverse effect was grade 3/4 mucositis (28.2%). No patient died due to protocol-related adverse effects. Multivariate analysis revealed the following independent prognostic factors: oropharyngeal cancer, extracapsular spread, and total radiation dose. Two-year progression-free survival and overall survival rates were 70.9% and 79.5%, respectively.

Conclusion: Modified weekly cisplatin-based chemotherapy is an acceptable regimen in postoperative CCRT for LAHNC.

Citing Articles

Analysis of Curative Effect and Prognostic Factors of Radiotherapy for Esophageal Cancer Based on the CNN.

Zhao Y, Xu J, Chen Q J Healthc Eng. 2021; 2021:9350677.

PMID: 34868534 PMC: 8639232. DOI: 10.1155/2021/9350677.

Weekly Chemotherapy of 5-Fluorouracil plus Cisplatin Concurrent with Radiotherapy for Esophageal Squamous Cell Carcinoma Patients with Postoperative Locoregional Recurrence: Results from a Phase II Study.

Chen B, Li Q, Li Q, Qiu B, Xi M, Liu M Oncologist. 2019; 25(4):308-e625.

PMID: 31880371 PMC: 7160409. DOI: 10.1634/theoncologist.2019-0931.

Clinical, pathophysiologic, and genomic analysis of the outcomes of primary head and neck malignancy after pulmonary metastasectomy.

Lu H, Hsieh C, Yeh C, Yeh Y, Wu C, Wang F Sci Rep. 2019; 9(1):12913.

PMID: 31501464 PMC: 6733860. DOI: 10.1038/s41598-019-49212-y.

Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis.

Lee S, Choi Y, Song I, Park S, Keam B, Yang Y Medicine (Baltimore). 2018; 97(21):e10778.

PMID: 29794758 PMC: 6392979. DOI: 10.1097/MD.0000000000010778.

The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis.

Jacinto J, Co J, Mejia M, Regala E Br J Radiol. 2017; 90(1079):20170442.

PMID: 29053029 PMC: 5963366. DOI: 10.1259/bjr.20170442.

References

Hansen D, Higgins P, Warner C, Mayo M . Exploring family relationships through associations of comfort, relatedness states, and life closure in hospice patients: A pilot study. Palliat Support Care. 2014; 13(2):305-11. DOI: 10.1017/S1478951514000133. View

Hu M, Wang L, Lu H, Chu P, Tai S, Lee T . Cisplatin-based chemotherapy versus cetuximab in concurrent chemoradiotherapy for locally advanced head and neck cancer treatment. Biomed Res Int. 2014; 2014:904341. PMC: 4109223. DOI: 10.1155/2014/904341. View

Trotti A, Colevas A, Setser A, Rusch V, Jaques D, Budach V . CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 13(3):176-81. DOI: 10.1016/S1053-4296(03)00031-6. View

Cooper J, Pajak T, Forastiere A, Jacobs J, Campbell B, Saxman S . Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004; 350(19):1937-44. DOI: 10.1056/NEJMoa032646. View

Bachaud J, Cohen-Jonathan E, Alzieu C, David J, Serrano E, Daly-Schveitzer N . Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys. 1996; 36(5):999-1004. DOI: 10.1016/s0360-3016(96)00430-0. View

Ho D, Pazdur R, COVINGTON W, Brown N, Huo Y, Lassere Y . Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res. 1998; 4(9):2085-8. View

Bernier J, Cooper J . Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence?. Oncologist. 2005; 10(3):215-24. DOI: 10.1634/theoncologist.10-3-215. View

Chan A, Leung S, Ngan R, Teo P, Lau W, Kwan W . Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005; 97(7):536-9. DOI: 10.1093/jnci/dji084. View

Adelstein D, Saxton J, Rybicki L, Esclamado R, Wood B, Strome M . Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol. 2006; 24(7):1064-71. DOI: 10.1200/JCO.2005.01.5867. View

10.

Bernier J, Vermorken J, Koch W . Adjuvant therapy in patients with resected poor-risk head and neck cancer. J Clin Oncol. 2006; 24(17):2629-35. DOI: 10.1200/JCO.2005.05.0906. View

11.

Seiwert T, Salama J, Vokes E . The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol. 2007; 4(3):156-71. DOI: 10.1038/ncponc0750. View

12.

Salama J, Seiwert T, Vokes E . Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol. 2007; 25(26):4118-26. DOI: 10.1200/JCO.2007.12.2697. View

13.

Lue B, Huang T, Chen H . Physical distress, emotional status, and quality of life in patients with nasopharyngeal cancer complicated by post-radiotherapy endocrinopathy. Int J Radiat Oncol Biol Phys. 2007; 70(1):28-34. DOI: 10.1016/j.ijrobp.2007.06.053. View

14.

De La Torre A, Garcia-Berrocal M, Arias F, Marino A, Valcarcel F, Magallon R . Preoperative chemoradiotherapy for rectal cancer: randomized trial comparing oral uracil and tegafur and oral leucovorin vs. intravenous 5-fluorouracil and leucovorin. Int J Radiat Oncol Biol Phys. 2007; 70(1):102-10. DOI: 10.1016/j.ijrobp.2007.05.068. View

15.

Chang P, Chen P, Chu P, Wang L, Tai S, Tsai T . Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. Cancer Chemother Pharmacol. 2008; 63(1):9-17. DOI: 10.1007/s00280-008-0702-1. View

16.

Lassen P, Eriksen J, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J . Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. 2009; 27(12):1992-8. DOI: 10.1200/JCO.2008.20.2853. View

17.

Rogers L, Rao K, Malone J, Kandula P, Ronen O, Markwell S . Factors associated with quality of life in outpatients with head and neck cancer 6 months after diagnosis. Head Neck. 2009; 31(9):1207-14. DOI: 10.1002/hed.21084. View

18.

Fesneau M, Pointreau Y, Chapet S, Martin L, Pommier P, Alfonsi M . Concomitant chemoradiotherapy using carboplatin, tegafur-uracil and leucovorin for stage III and IV head-and-neck cancer: results of GORTEC Phase II study. Int J Radiat Oncol Biol Phys. 2009; 76(1):154-63. DOI: 10.1016/j.ijrobp.2009.01.033. View

19.

Nakayama T, Noguchi S . Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan. Oncologist. 2010; 15(1):26-36. PMC: 3227888. DOI: 10.1634/theoncologist.2009-0255. View

20.

Pituskin E, Fairchild A, Dutka J, Gagnon L, Driga A, Tachynski P . Multidisciplinary team contributions within a dedicated outpatient palliative radiotherapy clinic: a prospective descriptive study. Int J Radiat Oncol Biol Phys. 2010; 78(2):527-32. DOI: 10.1016/j.ijrobp.2009.07.1698. View